European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
National Institute for Health and Welfare (THL), Helsinki, Finland.
Epidemiol Infect. 2013 Mar;141(3):651-66. doi: 10.1017/S0950268812001136. Epub 2012 Jun 12.
Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5-12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01-0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4-8 years between doses (OR 0·08, 95% CI 0·01-0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4-8 years between doses.
最近在一些高接种率人群中记录到了腮腺炎暴发。我们将来自参与欧洲血清流行病学网络（ESEN）的 18 个欧洲国家的血清阳性率、流行病学和疫苗接种数据与他们发生腮腺炎暴发的风险相关联，以提供疫苗接种策略信息。从国家人群血清库中采集样本，检测腮腺炎 IgG 抗体，并进行标准化，以便进行国际比较。使用特定年龄的腮腺炎血清阳性率数据以及报告的腮腺炎发病率、疫苗株、疫苗接种计划和血清采集后 5-12 年的疫苗覆盖率信息，对国家间进行了比较分析。在腮腺炎暴发国家中，平均几何平均腮腺炎抗体滴度较低（比值比[OR] 0·09，95%置信区间[CI] 0·01-0·71）。在多变量模型中，MMR1 疫苗覆盖率 ⩾95%仍然具有保护作用（P < 0·001），剂量间隔 4-8 年也是如此（OR 0·08，95%CI 0·01-0·85）。预防暴发和控制腮腺炎可能需要多个因素，包括高覆盖率的 MMR 疫苗接种计划，且剂量间隔为 4-8 年。
